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Objectives: Knee osteoarthritis (OA) is thought to be a slowly evolving disease with glacial changes in
cartilage morphology necessitating trials of potential treatments lasting 1e2 years with evidence that
over 6 months change in cartilage is not detectable. In contrast to cartilage, bone has the capacity to
adapt rapidly, such as after fracture. We tested whether bone marrow lesions (BMLs) change in
volume in 6 and 12 weeks, suggesting they may provide evidence of short term ﬂuctuations of joint
damage.
Methods: In 62 patients with patellofemoral knee OA (mean age 55.7 years, 59.7% women, mean BMI
31.0), we obtained baseline, 6 and 12 week knee MRIs with contrast enhancement. Of those with BMLs at
baseline, we assessed BML volume on the axial proton density fat saturated (FS) images and postcontrast
sagittal T1 weighted FS images. We manually segmented BML volumes, testing repeatability of BML
volumes in knees remeasured. Using the standard deviation of the difference between repeated
measurements to calculate BlandeAltman Limits of Agreement, we determined how much BML volume
change represented a change greater than due to chance.
Results: Fifty-two patients had BMLs at baseline. Testeretest reliability for BML volume was high (ICC
0.89, 95% CI 0.80e0.97). All knees showed at least some change in BML volume by 6 and 12 weeks. On the
axial view at 6 weeks, 20/49 (40.8%) knees showed BML volume changes greater than the limits of
agreement with similar results at 12 weeks. BML changes were evenly divided among knees with
enlarging and shrinking BMLs. 63.3% of the knees had more than 50% change in BML volume at either
6 or 12 weeks on the axial view and 48.7% on the sagittal view.
Conclusions: Knee BML volumes change in several weeks in many persons with knee OA. To the extent
that they could be regarded as treatment targets, trials testing BML effects could avoid the usual pro-
longed structure modiﬁcation trials.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license.Introduction
Knee osteoarthritis (OA) is thought to be a slowly evolving
disease with glacial changes in cartilage morphology necessitating
trials of potential treatments lasting 1e2 years. There is evidence
that change in cartilage over 6 months using quantitative
cartilage morphometry is not detectable1. The slow evolution of
structural disease has been thought to be a major impediment to
the rapid evaluation of promising treatments and makes it difﬁcult
to gauge whether treatments have structural effects on disease.
In contrast to cartilage, bone has the capacity to adapt rapidly.
Bone marrow lesions (BMLs) show evidence histologically of boneD.T. Felson, Arthritis Research
chester, UK.
dfelson@bu.edu (D.T. Felson).
ternational. Published by Elsevierdamage or microfracture2 and are related to malalignment3 and to
pain4,5. BMLs have been shown to change in volume at 1 year of
follow-up6, and one study evaluating biochemical markers of
cartilage metabolism in which repeated MRI’s were acquired and
scored semiquantitatively suggested that some knees had a change
in BML volumes over 3 months7.
There is a long history in medicine of intermediate outcomes
being used as treatment targets for disease when the ultimate
outcome occurs too infrequently (or too slowly) for trials to use it as
an outcome. Examples include focussing on hypertension instead of
its dreaded outcome, stroke and bone density instead of fracture.
There is already evidence that BMLs are strongly related to
outcomes of interest in OA; they increase the risk of cartilage loss1;
of OA progression by X-ray3, and of the development of knee
pain8,9. To examine their potential value as outcomes in short term
OA trials, it is necessary to determine whether they often change
over periods shorter than 1 year, suggesting that, as therapeuticLtd. Open access under the Elsevier OA license.
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for disease in short term trials.
Using a rigorous quantitative assessment of BML volume and
frequent knee MRI’s, we sought to evaluate whether BML volumes
in a knee changed within 6 or 12 weeks and how often this
occurred.
Methods
Patients in this study were enrolled in an ongoing randomised
trial of a patellofemoral (PF) brace for the treatment of patellofe-
moral osteoarthritis (PFOA). As such, all patients had to have
evidence of knee pain on most days originating predominantly in
the PF joint on physical examination and had to have evidence on
imaging studies (X-ray or MRI) or arthroscopy of OA in the PF joint.
For X-rays, we required a deﬁnite osteophyte and joint space nar-
rowing in the PF joint on skyline or lateral knee radiographs. For
MRI and arthroscopy, we required typical changes of OA with at
least cartilage loss present in the PF joint. After baseline assess-
ment, subjects underwent contrast enhanced (CE) baselineMRI and
then obtained CE MRI’s again using the same protocol and same
magnet at 6 and 12 weeks. We obtained our MRI’s with contrast
because BMLs were not the only focus of the study. Subjects
underwent a check of their estimated glomerular ﬁltration rate
(EGFR) to ensure adequate renal function (EGFR 45 cc/min) prior
to consent, and the study was approved by Stockport Research
Ethics Committee. We studied one knee per person.
MRI methods
Using a 1.5 T Philips MRI, we obtained axial Proton Density
Weighted (PDW) Fat Saturated (FS) repetition time (TR) 1500 ms,
echo time (TE) 15 ms, Field of View (FOV) 16 cm, 256  256 matrix,
slice thickness 3 mm with 0.3 mm gap and T1 weighted sagittal
postcontrast scans FS TR 500 ms TE 17 ms FOV 16 cm, 384  384
matrix slice thickness 3 mm with 0.3 mm gap in all subjects at
baseline, 6 and 12 weeks. Contrast agent was Dotarem at a dose of
0.2 mg/kg. Postcontrast images have been shown10to provide
similar assessments of BMLs as PDW FS non-CE images. Technicians
underwent extensive training from an experienced musculoskel-
etal radiologist (CEH), in which they were taught how to differen-
tiate BMLs from fat saturation failure, bone necrosis,
haematopoietic marrow and other ﬁndings. During the process of
segmentation, the radiologist reviewed any lesions where ques-
tions were raised about the nature and size of the lesion and, in
addition, he reviewed the 10% of knees that showed the greatest
change either at 6 or 12weeks to ensure that these changes were, in
reality, changes in BML volumes.We asked technicians at iMorphics
tomanually segment BML volumes inwhich BML areas on eachMRI
slice were outlined extending from the subchondral bone plate to
the farthest depth of their extension into cancellous bone. CysticTable I
Descriptive statistics of the study sample
Statistic (recorded at baseline visit) Whole sample (N ¼ 62
Age (years), mean (SD) 55.12 (7.84)
BMI (kg/m2), mean (SD) 30.97 (5.80)
Females, frequency (%) 37 (59.68%)
KOOS pain subscale score* (0e100), median (IQR) 47.22 (38.89e58.33)
Pain on nominated activity VASy (0e10), median (IQR) 7.20 (5.90e8.30)
Pain in last week VASy (0e10), median (IQR) 6.40 (4.60e7.70)
* Scoring for KOOS pain subscale is from 100 (no pain) to 0 (extreme pain).
y Scoring for the VAS is from 0 (no pain) to 10 (extreme pain).
z Represents the axial and sagittal samples after excluding knees whose segmentationchanges within BMLs were included in the BML volumes. We used
the axial PD and sagittal postcontrast images to carry out this work.
For the axial images only, we focused on the patella and femur only
which were consistently visualised on all axial images. For sagittal
images, we segmented BMLs in patella, femur and tibia. The areas
were then summed to compute BML volume. Sagittal and axial
were segmented at different times so that all images from a knee
were not analysed together. To optimise our ability to detect
changes in BML volumes, segmentations were carried out paired e
a speciﬁc knee’s repeated MRIs were segmented before moving to
the next knee. The segmenter was blinded both to the focus of this
study and to any treatment. Each subject was randomised to
immediate vs delayed treatment so that all subjects would have
received treatment by 12 weeks. Study personnel were blinded to
randomisation code. While we often conﬁrmed BML changes by
comparing ﬁndings in the two orthogonal planes, we focus here on
ﬁndings from each plane separately, since the two did not neces-
sarily reveal the same BML volumes and since the sagittal plane
provided the only data on tibial BMLs. Our focus here is on BML
volumes in each of the bones, not the volume of each BML, so that
we do not report on BMLs which merged or split during follow-up.
To evaluate repeatability of BML volume segmentations, at
a time at least 1 month after the initial work, the segmenter was
asked to resegment knees, randomly selected from those that had
been previously segmented with new ID numbers assigned (we
resegmented 24 axial images and 16 sagittal ones).
Using the standard deviation of the difference between repeated
measurements to calculate BlandeAltman Limits of Agreement11,
we determined how much BML volume change represented
a change greater than due to chance. We labelled this volume
change as the minimum detectable change (MDC), a threshold
above which changes would exceed those expected using the
BlandeAltman Limits of Agreement approach. This method has
been previously described as a particularly conservative boundary
for MDC limits12. We did this separately for each of the axial and
sagittal images. To determine the proportion with BML change
greater thanMDC, we divided all knees into thosewith any increase
in BML volume vs those with any decrease in volume. To examine
the relation of axial and sagittal BML volumes, we carried out
a random-effects multiple regression model testing whether the
axial volumes predicted sagittal volumes.
Results
A total of 62 subjects were studied (for characteristics of the
sample, see Table I). Of these we segmented BMLs at three time
points per person for axial view in all patients, and for sagittal
postcontrast view in 48 patients. Of these 62, 10 had no BMLs on
axial view at baseline. Of the remaining 52 images we rejected axial
segmentations for three knees based on quality concerns, leaving
49 subjects in our axial data set. Of the 48 sagittals, three of them) Axial sample (N ¼ 59z) Sagittal postcontrast sample (N ¼ 40z)
54.93 (7.92) 54.25 (7.12)
30.91 (5.80) 30.39 (5.98)
35 (59.32%) 23 (57.50%)
47.22 (36.11e58.33) 47.22 (36.11e58.33)
7.20 (5.90e8.40) 6.80 (5.90e8.40)
6.30 (4.40e7.50) 6.20 (4.60e7.20)
s were rejected for quality control reasons but includes knees without BMLs.
Axial
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Fig. 1. Change in BML volume on axial view, compared with BlandeAltman limits, at weeks 6 (left) and 12 week (right).
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we rejected eight segmentations based on quality control concerns,
leaving 37 in the sagittal data set.
Testeretest reliability for the total BML volumes for the scans
measured repeatedly showed ICC for axial views ¼ 0.81 and ICC for
sagittal views ¼ 0.60. The BlandeAltman 95% limits of agreement
for the axial images, assuming a zero-difference mean (no change
in BML volume), were 733 mm3 to þ733 mm3. For sagittal views,
the 95% limits of agreement were 5669 mm3 to þ5669 mm3
When we restricted sagittal BMLs to the femur and patella, the
same bones as in the axial view, we found a strong relationship
between axial and sagittal postcontrast BML volumes (r2 ¼ 0.78,
P<0.001), with sagittal volumes predicting slightly higher volumes
of BMLs than the axial view.
Axial view
In the 49 knees with BMLs, median BML volume at baseline was
1058mm3 (IQR 249mm3e2789mm3). All of these knees showed at
least some change in BML volume by 6 and 12 weeks (see Fig. 1). An
example of one knee showing shrinking BML volume on the axial
view is shown in Fig. 2. Using the BlandeAltman Limits of Agree-
ment as the threshold for minimal detectable change (MDC) on the
axial view,11 knees showed an increase in BML, and nine a decrease
at 6 weeks. Thus, 20/49 knees (40.8%) showed change beyond theFig. 2. Example of a patient with a patellar lesion changingMDC at 6 weeks. When we looked at change from baseline to
12 weeks, we found eight knees that had an increase and 11 knees
with a decrease beyond the BlandeAltman based MDC threshold
(19/49, 38.8%). We note that most knees in our sample had small
volumes of BMLs at baseline, with 24/49 (49.0%) having values less
than 1000mm3 at baseline. ReachingMDC using the BlandeAltman
Limits of Agreement method would have meant that BML volume
in these knees needed to change by almost 100%. To examine
a relative (percent) change in BML volume, we evaluated the
proportion of knees with more than 50% change in either direction
(i.e., either positive or negative) in BML volume from baseline to
either 6 and/or 12 weeks (Table II). Of the 49 knees with BMLs at
baseline, only 36.7% (18 knees) did not show BML volume change
by >50% at either 6 or 12 weeks.
Sagittal view
When we examined change in BML volume using the sagittal
postcontrast enhanced images, our results were similar although
the BlandeAltman limits were considerably wider, meaning that
substantial changes in volumes did not sometimes meet these
greater thresholds for MDC. When we examined change in BML
volume greater than these limits of agreement, we found that
3/37 (8.1%) had change at 6 weeks and that 6/37 had change at
12 weeks (16.2%). When we examined how many of these kneesover 12 weeks (denoted by white arrow) e axial view.
Table II
Proportion of knees with >50% change (either positive or negative) in total BML
volume at 6 or 12 weeks
Knees (frequency) Knees (%)
Axial view
Change 50% 18 36.73
>50% Change at only 6 weeks 8 16.33
>50% Change at only 12 weeks 8 16.33
>50% Change at both 6 and 12 weeks 15 30.61
Total 49 100.00
Sagittal postcontrast view
Change 50% 19 51.35
>50% Change at only 6 weeks 9 24.32
>50% Change at only 12 weeks 4 10.81
>50% Change at both 6 and 12 weeks 5 13.51
Total 37 100.00
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that 19/37 (51.4%) did not show at least 50% change and that >50%
change in BML volume occurred at either 6 or 12 weeks or both
times in the remaining 48.6% (18/37). Examples of BML changes on
the sagittal postcontrast view are shown in Figs. 3 and 4.Discussion
In many knees with OA, the volume of BMLs changes in 6e12
weeks, and to the extent that these changes can be affected by
treatment, this rapid change could be used to evaluate the course
of disease or the effect of treatment.
One other group has also noted change in BMLs in less than
a year, although not over such a brief time period as in our study.
Garnero and colleagues using the WORMS semiquantitative scale
reported that 28.6% of knees with OA showed change in BMLs at
3 months7. Like ours, these were subjects in an OA clinical trial,
although the time course of the MRI’s in relation to treatment is
unknown, MRI magnets varied from 0.2 T to 1.5 T, and individual
subjects may have obtained their scans in different magnets at
different times.
Other groups have documented changes in BML volumes over
1 year or more6,13,14 and, like our ﬁndings, published results suggest
that enlargement of lesions is more common than shrinkage,
although there was change seen in both directions.
Volume assessment of BMLs is challenging because they are
poorly circumscribed lesions, making it difﬁcult to deﬁne their
borders. We carefully reviewed the segmentations done for this
analysis and rejected several based on concerns that the volumes
were incorrectly assessed because of these challenges. However,
the volume changes in many of these lesions were unequivocal andFig. 3. Example of a patient with a patellar lesion changing over 12were seen in both planes of segmentation and by our radiologist
reviewing the images. It is likely that the changes we saw are large
enough to be detected also by semiquantitative assessment of BMLs
using approaches such as the WORMS scale or others. We have
presented preliminary evidence15 showing a high cross sectional
correlation of BML volumes and WORMS BML scores. If BML
changes were detected sensitively with semiquantitative scoring,
this could shorten image analysis time.
One potential limitation of our work is that we used different
imaging approaches to assess BMLs, using a postcontrast sagittal
image and a PDWaxial one. While these two approaches have been
reported10 to provide the same assessments of BMLs, the post-
contrast image showed slightly greater volumes even when
restricted to the same regions of the knee.
What changes canwe expect on the basis of biology? Since BMLs
show evidence of bone trauma on histology, the best parallel might
be fracture healing which occurs over weeks. The most common
pattern in our group was not healing, however, but rather
enlargement of lesions, a phenomenon seen also in the other
longitudinal studies in OA7. We note that BMLs are strongly related
to focal overloading in the joint, usually from malalignment3. We
are unsure whether the rapid change in volume of these lesions
reﬂects ﬂuctuation in the mechanical environment of the joint or
rather evanescent pathology than has not heretofore been
described, such as oedema or inﬂammation which might be ex-
pected to ﬂuctuate more than joint mechanics.
Further work is needed to clarify the clinical meaning of these
short term changes. For example, while longer term BML changes
correlate with ﬂuctuations in knee pain9, it is not clear whether
short term volume changes in BMLs have similar clinical relevance.
In conclusion, BMLs, lesions visible on MRI in the knee,
commonly ﬂuctuate in volume over 6e12 weeks. If these short
term volume changes are inﬂuenced by treatment, our ﬁndings
suggest that BMLs would be a convenient target for structure-
modifying treatments.Contributions
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